Aytu Biopharma, Inc.
AYTU
$2.13
-$0.05-2.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 62.64M | 63.70M | 66.38M | 65.84M | 61.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62.64M | 63.70M | 66.38M | 65.84M | 61.41M |
| Cost of Revenue | 20.77M | 20.66M | 20.55M | 19.21M | 17.23M |
| Gross Profit | 41.87M | 43.03M | 45.83M | 46.63M | 44.18M |
| SG&A Expenses | 39.09M | 37.75M | 38.29M | 39.26M | 40.14M |
| Depreciation & Amortization | 2.81M | 3.21M | 3.68M | 3.68M | 3.68M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.05M | 62.52M | 63.85M | 64.30M | 63.65M |
| Operating Income | -413.00K | 1.18M | 2.54M | 1.54M | -2.24M |
| Income Before Tax | -24.24M | -13.28M | -13.75M | 3.16M | -2.42M |
| Income Tax Expenses | 315.00K | 32.00K | 437.00K | 841.00K | 1.48M |
| Earnings from Continuing Operations | -24.56 | -13.31 | -14.18 | 2.32 | -3.91 |
| Earnings from Discontinued Operations | 116.00K | 239.00K | 620.00K | -681.00K | -1.33M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.44M | -13.07M | -13.56M | 1.64M | -5.24M |
| EBIT | -413.00K | 1.18M | 2.54M | 1.54M | -2.24M |
| EBITDA | 3.89M | 5.89M | 7.77M | 7.04M | 3.48M |
| EPS Basic | -3.11 | -1.93 | -1.90 | 0.20 | -0.97 |
| Normalized Basic EPS | -1.17 | -0.34 | -0.23 | 0.79 | 0.23 |
| EPS Diluted | -3.84 | -3.05 | -3.13 | -1.03 | -1.76 |
| Normalized Diluted EPS | -1.33 | -0.55 | -0.46 | 0.57 | 0.11 |
| Average Basic Shares Outstanding | 32.40M | 28.50M | 25.13M | 23.95M | 23.35M |
| Average Diluted Shares Outstanding | 44.51M | 42.96M | 32.58M | 31.41M | 28.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |